Determination and significance of serum inflammatory factors and biochemical indices in patients with Alzheimer′s disease and vascular dementia

doi:10.3969/j.issn.1673-8640.2016.05.005

Abstract

Abstract:

Objective To analyze the changes of serum inflammatory factors and biochemical indices in patients with Alzheimer′s disease（AD） and vascular dementia（VD）,and to provide a reference for clinical diagnosis. Methods A total of 37 AD patients,36 VD patients and 37 healthy subjects （control group） were enrolled. Serum inflammatory factors [interleukin 1 alpha （IL-1α）,interleukin 1 beta（IL-1β）,interleukin 6（IL-6） and tumor necrosis factor-alpha（TNF-α）] and biochemical indices such as free fatty acid（FFA）,total cholesterol（TC）,triglyceride（TG）,high-density lipoprotein cholesterol（HDL-C）,low-density lipoprotein cholesterol（LDL-C）,apolipoprotein A（apo A）,apolipoprotein B（apo B）,apolipoprotein E（apo E）,lipoprotein（a）[Lp（a）]and homocysteine （Hcy） were determined. The changes were evaluated among the groups. Results IL-1β,IL-6,TNF-α and Hcy were increased in AD and VD groups（P<0.05）,and HDL-C and apo A were decreased（P<0.05）. LDL-C in VD group were increased compared with control group（P<0.05）,and TG in VD group was higher than those in AD and control groups（P<0.05）. The other indices had no statistical significance among AD,VD and control groups（P>0.05）. Conclusions The determination of serum inflammatory factors and biochemical indices might be helpful for the diagnosis of AD and VD.

Key words: Inflammatory factors, Biochemical indices, Alzheimer′s disease, Vascular dementia

CLC Number:

R446.1

DING Binbin, WU Jianmin, JIE Yong, SUN Ronglian, WANG Xiaoyan. Determination and significance of serum inflammatory factors and biochemical indices in patients with Alzheimer′s disease and vascular dementia[J]. Laboratory Medicine, 2016, 31(5): 363-367.

Figures/Tables 1

References 31

[1]	YIN RH,TAN L,JIANG T,et al.Prion-like mechanisms in Alzheimer′s disease[J]. Curr Alzheimer Res,2014,11(8):755-764.
[2]	QUERFURTH HW,LAFERLA FM.Alzheimer's disease[J]. Engl J Med,2010,364(6):588.
[3]	O'BRIEN JT,THOMAS A. Vascular dementia[J]. Lancet,2015,386(10004):1698-1706.
[4]	UENO M,CHIBA Y,MATSUMOTO K,et al.Blood-brain barrier damage in vascular dementia[J]. Neuropathology,2016,36(2):115-124.
[5]	KITAZAWA M,CHENG D,TSUKAMOTO MR,et al.Blocking IL-1 signaling rescues cognition,attenuates tau pathology,and restores neuronal β-catenin pathway function in an Alzheimer's disease model[J]. J Immunol,2011,187(12):6539-6549.
[6]	CHRISTOFFERSEN M,WOODWARD EM,BOJESEN AM,et al.Effect of immunomodulatory therapy on the endometrial inflammatory response to induced infectious endometritis in susceptible mares[J]. Theriogenology,2012,78(5):991-1004.
[7]	郑占杰,陈红,王金东,等. 高同型半胱氨酸血症与阿尔茨海默病精神障碍的相关性分析[J]. 中国健康心理学杂志,2015,23(1):4-8.
[8]	LI JG,PRATICÒ D.High levels of homocysteine results in cerebral amyloid angiopathy in mice[J]. J Alzheimers Dis,2015,43(1):29-35.
[9]	曹传伟,禤彩霞. 血管性痴呆和阿尔茨海默病患者血清甘油三酯及总胆固醇含量的变化[J]. 中国老年学杂志,2011,31(19):3813-3814.
[10]	FOLSTEIN MF,FOLSTEIN SE,MCHUGH PR.Mini-mental state. A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res,1975,12(3):189-198.
[11]	HAMILTON M.The assessment of anxiety states by rating[J]. Br J Med Psychol,1959,32(1):50-55.
[12]	汪向东,王希林,马弘.心理卫生评定量表手册[M].北京:中国心理卫生杂志社,1999:235-238.
[13]	中华医学会神经病学分会. 血管性痴呆诊断标准草案[J]. 中华神经科杂志,2002,35(4):246.
[14]	陈同伟. 不同程度阿尔茨海默病患者血清可溶性Fas及其配体水平的变化[J]. 检验医学,2015,30(6):564-566.
[15]	HENEKA MT,O′BANION MK. Infammatory processes in Alzheimer＇s disease[J]. J Neuroinmunol,2007,184(1-2):69-91.
[16]	HOOZEMANS JJ,VEERHUIS R,ROZEMULLER JM,et al.Neuroinflammation and regeneration in the early stages of Alzheimer′s disease pathology[J]. Int J Dev Neurosci,2006,24(2-3):157-165.
[17]	TIAN M,DENG YY,HOU DR,et al.Association of IL-1,IL-18,and IL-33 gene polymorphisms with late-onset Alzheimer′s disease in a Hunan Han Chinese population[J]. Brain Res,2015,1596:136-145.
[18]	WERSCHING H,DUNING T,LOHMANN H,et al.Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function[J]. Neurology,2010,74(13):1022-1029.
[19]	MCCADDON A,HUDSON P,DAVIES G,et al.Homocysteine and cognitive decline in healthy elderly[J]. Dement Geriatr Cogn Disord,2001,12(5):309-313.
[20]	顾向明,黄阶胜,李莹莹,等. 血清同型半胱氨酸与C反应蛋白在急性脑血管病诊断中的应用[J]. 检验医学,2015,30(4):337-340.
[21]	程清. 脂蛋白相关磷脂酶A2和同型半胱氨酸水平与动脉粥样硬化性心脑血管疾病关系的研究[J]. 检验医学,2015,30(1):40-43.
[22]	姜宇海,王亚平. 冠心病患者同型半胱氨酸的变化及其临床价值[J]. 检验医学,2014,29(5):576-577.
[23]	王国戗,杨彩玲,郭丽娟. 不同血压水平人群血管危险因子检测及其临床意义探讨[J]. 检验医学,2014,29(3):254-257.
[24]	瞿国英,林炜炜,戴越刚. 同型半胱氨酸水平与脑梗死患者传统危险因素的相关性分析[J]. 检验医学,2013,28(2):102-105.
[25]	NILSSON K,GUSTAFSON L,HULTBERG B.Relation between plasma homocysteine and Alzheimer＇s disease[J]. Dement Geriatr Cogn Disord,2002,14(1):7-12.
[26]	KÖSEOGLU E,KARAMAN Y. Relations between homocysteine,folate and vitamin B12 in vascular dementia and in Alzheimer disease[J]. Clin Biochem,2007,40(12):859-863.
[27]	WANG B,ZHONG Y,YAN H,et al.Meta-analysis of plasma homocysteine content and cognitive function in elderly patients with Alzheimer′s disease and vascular dementia[J]. Int J Clin Exp Med,2014,7(12):5118-5123.
[28]	CANKURTARAN M,YAVUZ BB,CANKURTARAN ES,et al.Risk factors and type of dementia:vascular or Alzheimer?[J]. Arch Gerontol Geriatr,2008,47(1):25-34.
[29]	CANKURTARAN M,YAVUZ BB,HALIL M,et al.Are serum lipid and lipoprotein levels related to dementia?[J]. Arch Gerontol Geriatr,2005,41(1):31-39.
[30]	DIAS IH,POLIDORI MC,LI L,et al.Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities[J]. J Alzheimers Dis,2014,40(2):399-408.
[31]	任昌菊,张超,鄢金柱,等. 载脂蛋白E基因多态性与中国人群散发型阿尔茨海默病相关性的Meta分析[J]. 中国循证医学杂志,2014,14(7):813-820.

组别	例数	IL-1α（pg/mL）	IL-1β（pg/mL）	IL-6（pg/mL）	TNF-α（fmol/mL）
AD组	37	36.67±24.23	69.94±45.36^*	10.22±4.89^*	8.62±2.55^*
VD组	36	34.35±20.29	63.68±30.44^*	10.69±6.45^*	8.83±2.74^*
正常对照组	37	31.57±12.93	44.15±6.97	6.19±1.94	7.01±1.62
组别	Hcy（µmol/L）	TG（mmol/L）	TC（mmol/L）	HDL-C（mmol/L）	LDL-C （mmol/L）
AD组	34.76±24.85^*	1.28±0.67^#	4.20±1.04	0.96±0.21^*	2.70±0.93
VD组	37.73±21.07^*	1.72±1.09^*	4.62±1.13	0.93±0.21^*	3.07±1.04^*
正常对照组	14.51±2.62	1.04±0.38	4.47±0.85	1.19±0.29	2.49±0.65
组别	apo A（g/L）	apo B（g/L）	apo E（mg/L）	Lp（a）（mg/L）	FFA （µEq/L）
AD组	1.34±0.22^*	0.78±0.21	38.51±14.42	142.0（12.0~604.0）	354.0（85.71~1 000.0）
VD组	1.36±0.21^*	0.88±0.25	41.99±18.79	103.5（20.0~841.0）	347.6（116.4~1 000.0）
正常对照组	1.53±0.10	0.82±0.22	42.82±14.40	133.0（15.0~473.0）	433.0（239.8~576.3）

组别	例数	IL-1α（pg/mL）	IL-1β（pg/mL）	IL-6（pg/mL）	TNF-α（fmol/mL）
AD组	37	36.67±24.23	69.94±45.36^*	10.22±4.89^*	8.62±2.55^*
VD组	36	34.35±20.29	63.68±30.44^*	10.69±6.45^*	8.83±2.74^*
正常对照组	37	31.57±12.93	44.15±6.97	6.19±1.94	7.01±1.62
组别	Hcy（µmol/L）	TG（mmol/L）	TC（mmol/L）	HDL-C（mmol/L）	LDL-C （mmol/L）
AD组	34.76±24.85^*	1.28±0.67^#	4.20±1.04	0.96±0.21^*	2.70±0.93
VD组	37.73±21.07^*	1.72±1.09^*	4.62±1.13	0.93±0.21^*	3.07±1.04^*
正常对照组	14.51±2.62	1.04±0.38	4.47±0.85	1.19±0.29	2.49±0.65
组别	apo A（g/L）	apo B（g/L）	apo E（mg/L）	Lp（a）（mg/L）	FFA （µEq/L）
AD组	1.34±0.22^*	0.78±0.21	38.51±14.42	142.0（12.0~604.0）	354.0（85.71~1 000.0）
VD组	1.36±0.21^*	0.88±0.25	41.99±18.79	103.5（20.0~841.0）	347.6（116.4~1 000.0）
正常对照组	1.53±0.10	0.82±0.22	42.82±14.40	133.0（15.0~473.0）	433.0（239.8~576.3）